ABSTRACT
OBJECTIVE: The Attitudes of Consumers Toward Health, Cough, and Cold (ACHOO) survey was developed to better inform health care providers on the natural history and impact of common cold and cough, and related consumer experience and behaviors. RESEARCH DESIGN AND METHODS: Randomly selected US Internet/mobile device users were invited to participate in an online survey (N = 3333) in October 2012. Response quotas modeled upon 2010 US Census data ensured a demographically representative sample. To reduce potential bias from the quota design, 75% of the completed surveys were randomly selected as the primary analysis pool. MAIN OUTCOME MEASURES: Survey questions assessed participant demographics, frequency and duration of cough/cold symptoms, impact of symptoms on daily life, treatment preferences, and knowledge about cough/cold pathophysiology. RESULTS: In the past year, 84.6% of respondents had experienced at least one cold. Colds typically started with sore/scratchy throat (39.2%), nasal congestion (9.8%), and runny nose (9.3%) and lasted 3-7 days. Cough, the most common cold symptom (73.1%), had a delayed onset (typically 1-5 days after cold onset) and a long duration (>6 days in 35.2%). Nasal congestion and cough were the most bothersome symptoms. Many respondents waited until symptoms were 'bad enough' (42.6%) or multiple symptoms were present (20.2%) before using nonprescription medications. Drivers of choice included effectiveness in relieving symptoms, safety, and past experience. Respondents rarely consulted clinicians regarding treatment, and more than three-quarters had never received instructions from a clinician on how to choose a nonprescription cough/cold medication. Misperceptions regarding etiology and treatment of the common cold were prevalent. The main limitation is potential recall bias, since respondents had to recall cough/cold episodes over the prior year. CONCLUSIONS: The ACHOO survey confirms that cold is a common, bothersome experience and that there are gaps in consumers' knowledge of pathophysiology and appropriate management of cough/cold.
Subject(s)
Attitude , Common Cold/drug therapy , Cough/drug therapy , Adolescent , Adult , Aged , Common Cold/epidemiology , Consumer Behavior , Cough/epidemiology , Female , Humans , Internet , Male , Middle Aged , Nonprescription Drugs/therapeutic use , Surveys and QuestionnairesABSTRACT
Symptom and medication use are the key outcomes for assessing the efficacy of subcutaneous (SCIT) and sublingual allergen immunotherapy (SLIT). Our objective was to explore the similarities and differences between existing scoring mechanisms used in clinical trials of SLIT for seasonal allergens and characterize the impact that such differences may have on efficacy reporting. Randomized, double-blind, placebo-controlled clinical trials investigating the efficacy of SLIT for seasonal allergic rhinitis (2009-2013) were selected for review. Simulated and published data were used to demonstrate differences in scoring methods. Symptom and medication scoring methods across trials, although all designed to achieve the same objective, included important differences. The maximum daily symptom score (DSS) can vary widely depending on the number of symptoms assessed, and terminology of symptoms is not consistent. Similarly, daily medication scoring (DMS) methods differ greatly among studies and are dependent on medications allowed and weighting of scores assigned to each medication. When published DSS and DMS scores were used to calculate simulated daily combined scores (DCSs) based on various published methods, changes from placebo ranged from 19% to 29% when assuming all variables other than the DSS and DMS methods were equal. Variations in trial design, analysis, and seasonal characteristics also have effects on symptom and medication scoring outcomes. We identified multiple differences in trial scoring methods and design that make comparison among trials difficult. Symptom, medication, or combined scores cannot be indirectly compared among trials without taking the methods of scoring and other trial differences into account.
Subject(s)
Rhinitis, Allergic, Seasonal/therapy , Sublingual Immunotherapy , Clinical Trials as Topic , Humans , Research Design , Visual Analog ScaleABSTRACT
The efficacy of single-allergen-specific immunotherapy in polysensitized subjects is a matter of debate. We therefore performed a post hoc analysis of pooled data from six randomized, double-blind, placebo-controlled trials (N = 1871) comparing the efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet (AIT), Grazax (Phleum pratense 75 000 SQ-T/2800 BAU, ALK, Denmark), in mono- and polysensitized subjects. A statistically significant reduction in the mean total combined symptom/medication score (TCS) of 27% was demonstrated in actively treated subjects compared with placebo (P < 0.0001). This was not dependent on sensitization status (P = 0.5772), suggesting a similar treatment effect in mono- and polysensitized subjects (i.e. reductions of the TCSs of 28% and 26%, respectively, both P < 0.0001). Finally, a comparable and favourable safety profile of grass AIT was demonstrated in the two subgroups. Thus, no difference in efficacy and safety of single-allergen grass AIT was observed between mono- and polysensitized subjects.
Subject(s)
Desensitization, Immunologic/methods , Plant Extracts/therapeutic use , Poaceae/immunology , Rhinitis, Allergic, Seasonal/drug therapy , Administration, Sublingual , Adult , Antigens, Plant/immunology , Child , Child, Preschool , Double-Blind Method , Female , Follow-Up Studies , Humans , Male , Patient Safety , Phytotherapy/methods , Randomized Controlled Trials as Topic , Rhinitis, Allergic, Seasonal/immunology , Rhinitis, Allergic, Seasonal/physiopathology , Risk Assessment , Severity of Illness Index , Tablets/administration & dosage , Treatment OutcomeSubject(s)
Asthma/etiology , Rhinitis, Allergic, Perennial , Rhinitis, Allergic, Seasonal , Adolescent , Asthma/epidemiology , Asthma/therapy , Child , Global Health , Humans , Prevalence , Rhinitis, Allergic, Perennial/complications , Rhinitis, Allergic, Perennial/diagnosis , Rhinitis, Allergic, Perennial/epidemiology , Rhinitis, Allergic, Perennial/therapy , Rhinitis, Allergic, Seasonal/complications , Rhinitis, Allergic, Seasonal/diagnosis , Rhinitis, Allergic, Seasonal/epidemiology , Rhinitis, Allergic, Seasonal/therapy , Risk Factors , World Health OrganizationABSTRACT
BACKGROUND: The Global Asthma Physician and Patient (GAPP) Survey is the first global quantitative survey designed to uncover asthma attitudes and treatment practices among separate groups of physicians and patients, with the goal of identifying barriers to optimal management. METHOD: A total of 5582 physician and patient interviews were conducted globally online, by telephone and face-to-face. This paper highlights key global findings from the adult arm (3559 interviews) conducted in 16 countries. RESULTS: Physician and patient responses were found to differ when respondents were asked the same set of questions. Perceptions of time spent on asthma education, the quality of physician-patient communications, awareness and experience of side effects and understanding and knowledge of treatment noncompliance were found to differ between these two sets of respondents. CONCLUSIONS: The GAPP Survey not only defines an unmet need in asthma treatment, but also reveals that there is a direct relationship between the quality of physician-patient communication, the level of treatment side effects and the extent of patient compliance. These survey findings highlight a clear need for improved patient-focused care in asthma.
Subject(s)
Asthma , Attitude of Health Personnel , Attitude to Health , Physician-Patient Relations , Adult , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Asthma/psychology , Data Collection , Humans , Patient Care , Patient Compliance , Patient Education as Topic , Practice Patterns, Physicians'ABSTRACT
Asthma in children results in a large negative global impact and its recent increase in prevalence demands an aggressive and comprehensive treatment program. Recently there has been increasing global cooperation for developing more standardized treatment plans to address this complex disease. Advances in our knowledge of the exact mechanisms of this disease continue to lead to better pharmacologic treatment options. A variety of medications are currently available for the treatment of both acute and chronic asthma symptoms. The importance of controller medications that affect the underlying inflammatory process has been emphasized in the most recent treatment recommendations. The initial choice of medications for asthma treatment is frequently based on the severity classification of the asthma symptoms. Severity classifications include mild intermittent, mild persistent, moderate persistent, and severe persistent. Guidelines for treatment options for each of these severity classifications are available which incorporate appropriate flexibility for such a dynamic disease. These guidelines are based on evidence of effectiveness, relative safety, and other factors. This article reviews many of these medications, their actions, side effects, relative efficacy, and their indications for pediatric asthma treatment.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-Agonists/administration & dosage , Adrenergic beta-Agonists/therapeutic use , Age Factors , Anti-Asthmatic Agents/administration & dosage , Asthma/classification , Asthma/diagnosis , Asthma/epidemiology , Asthma/etiology , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/therapeutic use , Child , Child, Preschool , Emergencies , Follow-Up Studies , Health Education , Humans , Infant , Placebos , Prospective Studies , Randomized Controlled Trials as Topic , Respiratory Function Tests , Respiratory Therapy , Risk Factors , Time FactorsABSTRACT
The incidence and severity of pediatric asthma continues to increase in developed countries throughout the world. In determining what works best in the management of the asthmatic child, outcome measurements specific for this population have been developed. There are three major categories of outcomes that should be addressed in pediatric asthma. First are the clinical and physiologic measurements, which include lung functions, clinical symptoms, and number of emergency department and hospital visits. Measurement of both generic and disease-specific health-related quality of life (HQL) is advocated because each provides complementary information about how the condition affects everyday functioning and well-being, and whether treatments have their intended effects. Finally, economic outcomes should be considered, which include direct costs, such as physician and medication costs, and indirect costs, such as missing school or the parents missing work due to their child's asthma.
Subject(s)
Asthma/therapy , Outcome Assessment, Health Care/methods , Child , Cost-Benefit Analysis , Disease Management , Humans , Quality of Life , Surveys and QuestionnairesABSTRACT
Most clinical studies of inhaled nasal corticosteroids have established comparable safety and efficacy; therefore, there remains little to distinguish the various products from each other in the treatment of allergic rhinitis. However, patient preference is recognized increasingly as an important factor in selecting appropriate treatment. This review discusses the different methodologies that have been used to measure patient preference for intranasal corticosteroids. Patient questionnaires and other instruments for assessment that are used to measure such preferences are discussed as well as several different study designs. Now, the challenge is to implement more studies that show the reliability and consistency of instruments used to assess patient preference.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Asthma/drug therapy , Patient Satisfaction , Administration, Inhalation , Administration, Intranasal , Adrenal Cortex Hormones/adverse effects , Consumer Product Safety , Controlled Clinical Trials as Topic , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Nasal Mucosa/drug effects , Patient Participation , Treatment OutcomeABSTRACT
BACKGROUND: Asthma treatment has broadened from managing clinical markers to incorporate factors that are most meaningful to patients, collectively called health-related quality of life (HQL). OBJECTIVE: To develop an asthma-specific HQL tool, meeting demands for brevity, usefulness and measurement precision. METHODS: The 20-item Sydney Asthma Quality of Life Questionnaire (AQLQ) and six additional items were studied using factor analysis, reliability and validity tests among asthma patients 14 and older. RESULTS: The 15-item Integrated Therapeutics Group Asthma Short Form (ITG-ASF) retains the validity of the AQLQ with improved scaling properties and interpretability. The ITG-ASF yields 6 scores: Symptom-Free Index, Functioning with Asthma, Psychosocial Impact of Asthma, Asthma Energy and Asthma-Confidence in Health and a Total. All items correlated 0.40 or higher with their hypothesized scales and passed discriminant validity tests, with scaling success rates from 75 to 100%. Reliability exceeded the minimum of 0.70 for group comparisons. Ceiling and floor effects were acceptable. Scales were valid in relation to changes in asthma severity and lung function. The best predictor of asthma severity (National Asthma Education and Prevention Program (NAEPP) staging) was the Symptom-Free Index. A Spanish translation is available, Chinese-American is forthcoming. The reading grade level is 4.8. CONCLUSIONS: Development of the ITG-ASF was a data-driven process maximizing measurement precision and breadth while minimizing burden. The ITG-ASF is a brief, comprehensive and empirically valid tool that complements traditional markers of the outcomes of asthma care.
Subject(s)
Asthma/rehabilitation , Health Status , Quality of Life , Surveys and Questionnaires , Adolescent , Adult , Aged , Factor Analysis, Statistical , Female , Humans , Male , Middle Aged , Psychometrics/methods , Reproducibility of Results , United StatesABSTRACT
The goals of asthma treatment have broadened beyond managing traditional clinical markers of disease severity, and now include a focus on benefits of treatment in terms that are most meaningful to patients. Measurement of both generic and disease-specific health-related quality of life (HQL) is advocated because each provides complementary information about how the condition affects everyday functioning and well-being and whether treatments have their intended effects. The purpose of this study was to determine the impact of changes in asthma severity (defined using NHLBI/NAEPP severity staging) on patient-assessed HQL. Two hundred and thirty-three pediatric asthma patients and 269 adult asthma patients were evaluated in a one-year observational study. Analyses were performed to compare the generic and asthma-specific scores for patients whose asthma severity improved, stayed the same, or worsened over one year. The asthma-specific scales are sensitive to changes in disease severity. Of the generic scales, those tapping areas of physical health are more affected than the mental/emotional scales. This confirms that HQL measures are responsive to changes in asthma severity. They complement traditional clinical markers used to evaluate changes in a patient's disease state and thus give the physician another useful tool in following the clinical progress of the child with asthma.
Subject(s)
Asthma/physiopathology , Outcome and Process Assessment, Health Care , Quality of Life , Severity of Illness Index , Adult , Child , Data Collection , Female , Humans , Male , Middle AgedSubject(s)
Asthma/physiopathology , Quality of Life , Rhinitis, Allergic, Seasonal/physiopathology , Adolescent , Child , Child, Preschool , Female , Humans , Male , Prognosis , Sickness Impact ProfileABSTRACT
Allergic rhinitis is a highly prevalent, chronic condition. In addition to physical discomfort, rhinitis symptoms have been associated with detrimental effects on the psychological and social aspects of patients' lives. In allergy-specific questionnaires, subjects with allergic rhinitis consistently report lower quality of life than nonallergic controls. Untreated patients are embarrassed and frustrated by their allergy symptoms. Atopic individuals consistently exhibit significant declines in cognitive processing, psychomotor speed, verbal learning, and memory during allergy season. The discomfort, cognitive impairment, and absenteeism associated with allergic rhinitis exact a significant economic toll on U.S. businesses through decreased productivity. When combined with direct medical expenditures, the economic burden of allergic rhinitis is considerable. The effect of treatment on the economics of allergic rhinitis is highly variable: relatively inexpensive medications (lower direct costs) have central nervous system side effects that can cause somnolence and impair learning, memory, and performance (higher indirect costs). Health outcomes data on the effects of allergic rhinitis and its treatments can help establish, monitor, and improve standards of care; as well as inform priority setting, direct resource allocation, and eliminate unnecessary practices.
Subject(s)
Cognition Disorders/etiology , Cost of Illness , Quality of Life , Rhinitis, Allergic, Perennial/economics , Rhinitis, Allergic, Perennial/therapy , Chronic Disease , Cognition Disorders/physiopathology , Female , Humans , Male , Rhinitis, Allergic, Perennial/diagnosis , Socioeconomic FactorsABSTRACT
OBJECTIVE: This review will familiarize clinical allergists/immunologists with the common forms of complementary/alternative medicine (CAM) that are being used frequently by their patients. It reviews reasons that patients seek alternative health care therapies and the most common illnesses that are treated with this form of medicine. Cultural differences in CAM are also reviewed. The article focuses on specific therapies used to treat asthma and reviews the efficacy of these therapies based on the available scientific literature. The reader will also learn about views of other physicians on CAM and how this topic is being addressed in US medical schools. DATA SOURCES: Computer-assisted MEDLINE searches for articles on "complementary/alternative medicine" or "herbal therapy" and "asthma" or "atopy." STUDY SELECTION: Pertinent abstracts and articles in the above areas were selected. Articles selected for detailed review included review articles of the subjects along with randomized, double-blind placebo-controlled studies in animals and humans. RESULTS: Complementary/alternative medicine is commonly used by patients with chronic conditions including asthma. One-third of the US population has tried CAM. The literature supporting the efficacy of these therapies is lacking. Some reports elucidate the mechanism of action of certain herbal therapies that could possibly be helpful in the treatment of allergic diseases. There are, however, few well-controlled studies that support the efficacy of CAM in the treatment and clinical improvement of human subjects with asthma or atopic disorders. CONCLUSION: Available scientific evidence does not support a role for CAM in the treatment of asthma. The studies in the literature often have significant design flaws that weaken the conclusions such as insufficient numbers of patients, lack of proper controls, and inadequate blinding. Further studies are needed to prove or disprove the efficacy of CAM. Physicians often find CAM intimidating because they are unaware of the clinical evidence and feel uncomfortable advising their patients on its efficacy. There is definitely a need for more education among physicians in this area. It is also important that physicians inquire and discuss the use of CAM with their patients since the majority of patients are using some form of CAM.
Subject(s)
Asthma/therapy , Complementary Therapies , HumansABSTRACT
OBJECTIVE: This review will furnish the reader current information on the importance of quality of life evaluation in patients suffering from allergic rhinitis, the different types of quality of life instruments used, and how they can be used in judging different pharmaceutical therapies. DATA SOURCES: Computer-assisted MEDLINE searches for articles assessing "quality of life" and "outcomes" in rhinitis. Also MEDLINE searches evaluating health-related quality of life in relationship to different pharmacologic treatments in allergic rhinitis. STUDY SELECTIONS: Pertinent abstracts and articles in two broad areas were selected. The first groups were articles in the fields of outcomes, quality of life, allergic rhinitis, and its relationship to health-related quality of life. The second group of articles evaluated different pharmacologic agents' effect on the health-related quality of life of rhinitis patients. Both sets of articles were critically analyzed with important representative studies selected for this review. RESULTS: Health-related quality of life of patients with allergic rhinitis is impaired as measured by both generic and specific health-related quality of life instruments. Use of second generation antihistamines, intranasal corticosteroids, and intranasal ipratropium bromide have been shown to improve the health-related quality of life of sufferers of allergic rhinitis. CONCLUSIONS: The measuring of health-related quality of life is assuming a primary position in outcomes analysis in the patient with allergic rhinitis. Studies have documented the validity of using generic and specific health-related quality of life instruments in allergic rhinitis. Each type has its own weaknesses and strengths that the user needs to appreciate. Appraising the role of different pharmacologic agents in allergic rhinitis in improving the patient's quality of life is an important part of proving the medication's worth to the health care community.
Subject(s)
Quality of Life , Rhinitis, Allergic, Perennial/psychology , Rhinitis, Allergic, Seasonal/psychology , Adolescent , Anti-Allergic Agents/therapeutic use , Controlled Clinical Trials as Topic , Humans , Rhinitis, Allergic, Perennial/drug therapy , Rhinitis, Allergic, Seasonal/drug therapySubject(s)
Food Hypersensitivity , Hypersensitivity , Female , Food Hypersensitivity/diagnosis , Food Hypersensitivity/epidemiology , Food Hypersensitivity/therapy , Humans , Hypersensitivity/diagnosis , Hypersensitivity/epidemiology , Hypersensitivity/therapy , Male , Prevalence , Risk Factors , Skin Tests , Women's HealthABSTRACT
Physicians, patients, employers, managed care organizations, insurance companies, and government all want to know how different approaches to management of asthma are improving care. To this end, the field of outcomes analysis in asthma is playing a major role. Clinical, physiologic, humanistic, and economic outcomes are being assessed using different types of general and asthma-specific instruments. Historically, clinical and physiologic outcomes have been of most concern to clinicians. However, humanistic outcomes, such as health-related quality of life and patient satisfaction, shift the focus to the patient. Economic outcomes, especially cost-effectiveness, evaluate how to achieve the best outcomes at the lowest cost. These outcomes have been used to evaluate asthma intervention programs. Several large asthma outcomes research projects, which should define the future of outcomes analysis in asthma, are under way.
Subject(s)
Asthma/therapy , Outcome Assessment, Health Care , Quality of Life , Asthma/economics , Cost of Illness , Cost-Benefit Analysis , HumansABSTRACT
BACKGROUND: Vocal cord dysfunction syndrome is often misdiagnosed as refractory asthma. Airway fluoroscopy has recently been proposed as an alternative to laryngoscopy in the initial evaluation of certain cases of suspected vocal cord dysfunction. OBJECTIVE: To evaluate the use of airway radiographs and fluoroscopy in a patient with suspected vocal cord dysfunction. METHODS: We used soft tissue technique airway radiographs and fluoroscopy to evaluate the glottic function during inspiration and expiration in a 9-year-old boy with refractory asthma and suspected vocal cord dysfunction. RESULTS: The study confirmed paradoxical vocal cord motion. CONCLUSIONS: Airway radiographs and fluoroscopy provide a rapid and noninvasive means of diagnosing vocal cord dysfunction. Patients should still have laryngoscopy performed at the earliest possible moment to rule out the possibility of other laryngeal abnormalities.
Subject(s)
Fluoroscopy , Vocal Cords , Child , Glottis/diagnostic imaging , Humans , Laryngeal Diseases/diagnosis , Male , Respiratory System/diagnostic imagingABSTRACT
Outcomes research is becoming an integral part of the sweeping changes occurring in the U.S. health care system. By developing outcomes monitoring systems in allergic disorders, allergists will be able to collect information showing their commitment to excellent clinical care, which improves the patient's quality of life in a cost-effective way. Outcomes data is also important in determining the number of allergists that need to be trained, appropriate therapeutic regimens for allergic disorders, evaluating differences in practice styles of allergists throughout the country, and in revising practice parameters in allergic disorders. Through the Joint Council of Allergy, Asthma, and Immunology, a subcommittee on outcomes was formed. This subcommittee awarded a national asthma outcomes monitoring project to The Health Institute, New England Medical Center, Boston. This project, which will be in three phases, will generate information on outcomes of board-certified allergists in asthma care. Another goal of this project will be to produce standardized instruments and collection methods, which will be made available for use by all allergists to collect their own outcomes data.